News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major news articles were published in the past hour.
  • Global equity and bond markets had no new catalysts reported in the last hour.
  • No fresh central bank announcements or policy moves occurred in the past hour.
  • No significant corporate earnings or M&A headlines emerged in the last hour.
  • No major geopolitical developments or conflicts were reported during the past hour.
  • Economic indicators and market-moving data releases were absent in the past hour.

Latest Articles

AirJoule Technologies Acquires BitSink, Adding Profitable AI & HPC Infrastructure Cooling Business

AirJoule Technologies Acquires BitSink, Adding Profitable AI & HPC Infrastructure Cooling Business

AirJoule Technologies Corporation has acquired BitSink, a U.S.-based company specializing in cooling and power distribution infrastructure for AI and high-performance computing data centers. This acquisition positions AirJoule as a broader infrastructure solutions provider, addressing critical constraints such as cooling, water, and power for next-…

Osisko Gold Announces Formal Construction Decision and Development Update for the Cariboo Gold Project

Osisko Gold Announces Formal Construction Decision and Development Update for the Cariboo Gold Project

Osisko Gold Group Inc. has officially approved the construction of its 100%-owned Cariboo Gold Project in British Columbia, targeting first gold production in Q1 2029 and commercial production by H2 2029. The project is supported by a $30 million strategic private placement and offtake agreements with Trafigura, along with a potential $120 million …

Ashland Innovation Day to be held September 17, 2026

Ashland Innovation Day to be held September 17, 2026

Ashland Inc. will host an Innovation Day webcast on September 17, 2026, where company leadership will present updated information on their innovative technology platforms, commercial progress, and scalability. The event aims to showcase advancements poised to impact key markets such as architectural coatings, construction, energy, food and beverage…

UMH PROPERTIES, INC. WILL ATTEND AND SHOWCASE TWO HOMES AT THE U.S. DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT’S ANNUAL INNOVATIVE HOUSING SHOWCASE

UMH PROPERTIES, INC. WILL ATTEND AND SHOWCASE TWO HOMES AT THE U.S. DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT’S ANNUAL INNOVATIVE HOUSING SHOWCASE

UMH Properties, Inc., a US-based REIT specializing in manufactured home communities, will present two innovative manufactured homes at the U.S. Department of Housing and Urban Development's annual Innovative Housing Showcase for the sixth year. The featured homes demonstrate advanced design and construction techniques enhancing affordable housing o…

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

GeNeuro, a US subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), announced the award of a European patent for GNK-301, a monoclonal antibody targeting the HERV K Envelope protein implicated in ALS. The patent complements two US patents and supports the technology to potentially modify ALS progression. GNK-301 manufacturing under cGMP is underway, wi…

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Holdings plc announced the successful enrollment of 540 patients in its registrational Phase 3 TEBE-AM trial assessing KIMMTRAK (tebentafusp) in previously treated patients with HLA-A*02:01-positive advanced melanoma. The trial evaluates KIMMTRAK as monotherapy and in combination with pembrolizumab against Investigator’s Choice, with ove…

Village Farms Appoints Deepak Anand to Lead Global Government Affairs

Village Farms Appoints Deepak Anand to Lead Global Government Affairs

Village Farms International has appointed Deepak Anand as Vice President of Government Affairs to lead global government relations and regulatory strategies. Anand's extensive experience in cannabis policy and international market development is expected to strengthen Village Farms' position and expansion in global cannabis markets. This strategic …

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics announced it will present initial clinical data from Part A of its ongoing Phase 1/1b trial of PAS-004, a novel oral MEK inhibitor for neurofibromatosis type 1 (NF1)-associated neurofibromas, at the 2026 European Neurofibromatosis Conference in Vienna. This marks the company's first public disclosure of clinical data for the d…

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Cullinan Therapeutics announced a virtual event to present interim Phase 3 REZILIENT3 trial data of zipalertinib plus chemotherapy in lung cancer, recently featured at the IASLC 2026 World Conference on Lung Cancer. The data, presented in a Presidential Symposium, highlights potential advancement in T cell engager therapeutics for cancer treatment.

Highwoods Announces Leasing and Disposition Activity

Highwoods Announces Leasing and Disposition Activity

Highwoods Properties announced signing 1.1 million square feet of second generation leases in Q3 2026, including over 200,000 square feet of new leases, reflecting robust leasing demand. The company closed $74 million in non-core disposals, part of its strategic asset sales totaling $374.8 million this year, aimed at optimizing portfolio and improv…

Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast plc Announces Intention to Voluntarily Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast plc announced its intention to voluntarily delist its Class A Ordinary Shares and Warrants from Nasdaq by October 2026 and deregister under the Exchange Act. The company plans to rename itself Milk Makeup plc to align with its sole operating brand after selling Obagi Medical. Post-delisting, Waldencast intends to seek quotation on an ove…

Brookfield to Host 2026 Investor Day on September 17

Brookfield to Host 2026 Investor Day on September 17

Brookfield Corporation (NYSE: BN) and Brookfield Asset Management (NYSE: BAM) will hold their Investor Day event in New York on September 17, 2026, offering live webcasts and presentations to provide updates on their business operations and strategic direction. The event aims to inform investors about the company's assets under management and long-…

Markets Brace for Fed Move as Oil Jumps and AI Leaders Urge a Pause

Markets Brace for Fed Move as Oil Jumps and AI Leaders Urge a Pause

Markets are pricing a Federal Reserve rate increase this Wednesday amid limited reassurance from last week's inflation reading and a fresh surge in oil prices after renewed Middle East hostilities. Simultaneously, prominent figures in the AI sector have urged a slowdown in development, prompting declines in AI-linked equities and raising the prospe…

Rollins Offered at a Steep Discount to Quality - A 180-Day Rebound Trade

Rollins Offered at a Steep Discount to Quality - A 180-Day Rebound Trade

Rollins (ROL) is a high-return recurring-revenue services business trading near its 52-week low after a margin miss and follow-on investor lawsuits. Fundamentals remain attractive - strong free cash flow, 37% ROE, moderate leverage and a growing dividend - while technicals show oversold conditions. This trade targets a mean-reversion to normalized …

Cespira™, the Joint Venture between Westport and Volvo Group, reveals how HPDI™ 3.0 advances fuel economy and expands OEM options

Cespira™, the Joint Venture between Westport and Volvo Group, reveals how HPDI™ 3.0 advances fuel economy and expands OEM options

Westport Fuel Systems and Volvo Group's joint venture, Cespira, announced the advanced HPDI 3.0 fuel system that improves fuel economy, hardware durability, and system integration for heavy-duty engines using LNG and bioLNG. The technology supports broader engine configurations and future fuels like hydrogen, with production beginning in late 2026 …

Parsons Operational, Agile, Defense Solutions Ready Now on Department of War’s Digital Marketplaces

Parsons Operational, Agile, Defense Solutions Ready Now on Department of War’s Digital Marketplaces

Parsons Corporation announced that nine of its digital defense solutions have been designated as 'Awardable' across two major Department of War digital marketplaces, Platform One and Tradewinds. This recognition facilitates faster government procurement and deployment of Parsons' innovative, mission-ready defense technologies, enhancing operational…